The majority of my interviews have been over the phone. As for how many interviews for feature articles I’ve conducted via Zoom, the number is exactly two — both appearing in this issue.

John Fowler had never worked in biopharma before. That didn’t stop his best friend — a scientist — from asking Fowler to lead the biotech startup he had been working on. It was a risk to both the company’s future — and their friendship.

Disruption of life routines by COVID-19 provide a CNS opportunity on multiple fronts. 

Joe Wolk’s father spent 40 years working at the nearby J&J manufacturing facility. Now, Joe has reached the top of the organization as CFO. His path getting there, though, didn’t start in pharma.

Our previous 16 regular issues of LSL (excluding the annual outlook issue) featured a biopharmaceutical company CEO on the cover. But our cover features aren’t limited to the CEO, as this month’s issue shows with our feature on J&J’s CFO Joe Wolk.

While biopharma's response to COVID-19 has started to turnaround the industry's sagging reputation, one successful response to one crisis does not a reputation save.

While working at a VC firm, Jay Luly, Ph.D., was tasked with assessing if Enanta Pharmaceuticals could be turned around, or if it should be shut down. Today the company is probably one of the most productive Big Pharma R&D engines you’ve never heard of — until now.

IBM and GE are some famous business-focused turnaround stories, but this month we;’ve got a memorable one from the biopharma industry.

Just as COVID changed our personal lives, it forced us to make changes to Life Science Leader, too. Ultimately, it is the reader who benefits from these changes, because we’re bringing you more of the content you want in more ways.